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Autoimmune pathology has been suggested as an aetiology for
some cases of schizophrenia, with increasing evidence implicating
N-methyl-D-aspartate receptor (NMDA-R) autoantibodies.1,2
NMDA-R hypofunction is postulated as a mechanism underlying
the development of schizophrenia.3 Support for this theory comes
from cases of NMDA-R encephalitis, which often presents with
symptoms of psychosis before rapidly progressing to seizures,
movement disorders, impaired consciousness, autonomic instability
and respiratory distress.4 Previous studies have identified serum
NMDA-R autoantibodies in 4.3% of a prospective cohort of
patients with first-episode psychosis2 and 9.9% of acutely ill
patients with schizophrenia – either in the first episode or
experiencing an acute exacerbation of their illness.1 These studies
indicate that 4–10% of patients in the first episode or acute phases
of schizophrenia have NMDA-R autoantibodies. A recent study
found that 10.5% of participants were seropositive for NMDA-R
antibodies with no difference in seroprevalence between patients
with schizophrenia and healthy controls.5 The same authors
demonstrated in animal studies that NMDA-R autoantibodies
have behavioural effects only in rodents with a compromised
blood–brain barrier. This led them to hypothesise that it is a
disruption of blood–brain barrier integrity in schizophrenia that
leads to NMDA-R autoantibodies being able to enter the brain
to a greater extent than in healthy controls. About one in three
patients with schizophrenia has a treatment-refractory condition
– defined by the National Institute of Health and Care Excellence
(NICE) as persistent psychotic symptoms despite at least two
adequate therapeutic trials of different antipsychotic drugs.6 In
contrast to the dopamine elevation seen in patients who respond
to treatment, patients with treatment- refractory psychosis have
been found to have normal dopamine synthesis capacity7 and
elevated glutamate levels.8 These findings are consistent with
NMDA-R hypofunction, leading to compensatory glutamate
excess in treatment-refractory illness. This would explain the lack
of response to dopamine-blocking antipsychotic drugs. From this
evidence, we hypothesised that NMDA-R hypofunction secondary
to NMDA-R autoantibodies underlie some cases of treatment-
refractory psychosis. We sought to test this by ascertaining the point
prevalence of NMDA-R antibody positivity in a sample of patients
with treatment-refractory psychosis.
Method
The sample consisted of 43 referrals (January 2011 to August
2013) to the services for treatment-refractory psychosis at South
London and Maudsley NHS Foundation Trust. Routine socio-
demographic and clinical data were collected as part of the
assessment. These related to gender, age, ethnicity, diagnosis,
duration of illness, response to treatment and NMDA-R auto-
antibody status. Inclusion criteria were meeting the ICD-10 criteria
for schizophrenia (F20) or schizoaffective disorder (F25),9 and
meeting the following criterion for treatment resistance:6 persistent
psychotic symptoms associated with distress and functional
impairment that have not responded to at least two adequate trials
of different antipsychotics. An adequate treatment trial was
defined as treatment at a dose within the British National Formulary
(www.bnf.org) therapeutic range for at least 6 weeks, with good
adherence indicated by receipt of a long-acting injection as
prescribed, or, for oral antipsychotics, a serum antipsychotic level
within the therapeutic range.
The primary outcome measure was seropositivity for
NMDA-R antibodies. A standardised cell-based assay was used
for the detection of serum immunoglobulin (IgG) antibodies
directed against the NR1 and NR2b subunits of the NMDA-R.10
This was performed by the Department of Clinical Neurology,
John Radcliffe Hospital, University of Oxford. Study approval
was granted by the Psychosis Clinical Academic Group Audit
committee at South London and Maudsley NHS Foundation
Trust, London UK. Every effort has been made to preserve the
anonymity of the patients in the case reports.
Results
The sample comprised 43 patients (32 males and 11 females; mean
age 40.3 years (s.d.= 11.1, range 20–69); schizophrenia, n=36;
schizoaffective disorder, n=7). The mean duration of illness was
15.7 years (s.d.= 9.4, range 2–37) and all met criteria for refractory
illness.6 Three patients were seropositive for IgG antibodies directed
against NMDA-R – giving a point prevalence of 7.0%. All had low
serum antibody titres (1:50, 1:50, 1:100). All three had normal
MRI brain imaging and none had a history of delirium, neurological
symptoms or signs, seizures or carcinoma. None of the patients had
an electroencephalogram or cerebrospinal fluid (CSF) analysis.
The first patient was a 30-year-old White man, with a 10-year
history of treatment-refractory paranoid schizophrenia, with a
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serum NMDA-R antibody titre of 1:50. The unremitting psychotic
illness was characterised by grandiose and religious delusions,
perceptual disturbances and conceptual disorganisation, as well
as negative symptoms such as poor self-care and social with-
drawal. His Brief Psychiatric Rating Scale-18 (BPRS-18)11 score
at the time of serum antibody testing was 63. The positive
antibody result was identified concurrent to ongoing clozapine
treatment. He displayed a good clinical response to maintenance
clozapine therapy – reflected in a reduction in the BPRS-18 score
to 30 after 6 months of treatment. A repeat NMDA-R antibody
test at 6 months after the initial assay was negative.
The second patient was a 31-year-old Black British man with a
3-year history of treatment-refractory paranoid schizophrenia. He
had a serum NMDA-R antibody titre of 1:100. His initial
presentation was marked by disorganisation of thought processes,
delusions of reference and perceptual disturbances – including
visual and command auditory hallucinations. The illness course
was characterised by persistent positive psychotic symptoms. He
had a BPRS-18 score of 52 on initial assessment, when he was
treated with paliperidone palmitate. A second serum titre taken
5 weeks after his first positive result was 1:50 indicating a
reduction in antibody levels without any noticeable change in
clinical presentation. He showed a good clinical response to
clozapine, demonstrated in a reduced BPRS-18 score of 31 after
5 months of clozapine treatment.
The third patient was a 41-year-old White woman. She had a
serum NMDA-R antibody titre of 1:50. She had a diagnosis of treat-
ment-refractory paranoid schizophrenia, with an illness duration of
16 years. Her illness was characterised by unremitting olfactory and
tactile hallucinations. She had aBPRS-18 score of 71. She had a history
of head injury with loss of consciousness but without sequelae. At
the time of the antibody assay she was treated with quetiapine.
She declined a change to her medication and her psychosis persists.
Discussion
This study found that 3 out of 43 patients (7.0%) with chronic
refractory psychosis were positive for NMDA-R autoantibodies.
These results do not support our hypothesis that NMDA-R
autoantibodies specifically underlie treatment-refractory schizo-
phrenia, although research in larger samples is needed. Given
recent evidence suggesting that seropositivity occurs in the acute
phase of illness for those with chronic psychoses,1 it is possible
that some of the seronegative patients with chronic refractory
psychosis were seropositive for NMDA-R autoantibodies earlier
in their illness. It is also possible that antipsychotic treatment
may have decreased antibody titres. Thus, we cannot exclude the
possibility that the patients had NMDA-R autoantibodies earlier
in their illness, and that the effects of this persisted after
NMDA-R antibody production had ceased. In all three of the
participants who were seropositive, the antibody titres were low.
The clinical significance of low titres in patients presenting with
refractory psychosis and without the characteristic clinical
syndrome remains to be determined. Although CSF and, to a
lesser extent, serum antibody titres have been shown to be related
to illness severity in NMDA-R encephalitis,12 a similar correlation
has not yet been demonstrated in any stage of psychosis. In this
study only serum samples were tested for the presence of
NMDA-R antibodies, and it may be that the sensitivity of antibody
testing could have been increased through the use of CSF.12 This
assertion remains controversial,10 and has not been assessed in a
population of individuals with treatment-refractory schizophrenia.
Limitations of our study were the relatively small sample size,
the lack of a control group and the preponderance of men in our
sample. The latter may be important, given evidence from studies
of NMDA-R encephalitis indicating that women are more likely to
be seropositive.4 Nevertheless, the excess of men in our sample is
typical of refractory schizophrenia.6
Our study findings do not support the hypothesis that
NMDA-R autoantibodies are a common aetiology in refractory
psychotic illnesses, although we cannot exclude a role for them
in the pathoaetiology of a subgroup of individuals. At present,
there is no evidence that this is a useful routine investigation in
refractory psychosis. However, further investigation is needed,
given that there is evidence that some people with psychosis
respond to immunomodulatory therapy.10
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